<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231113071535&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+8 629 3ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC- &amp;fc=20230708114047<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231113071535&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 13 日星期一 12:15:39 +0000</lastbuilddate><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>细胞周期蛋白 D-CDK4 二硫键减弱肺血管细胞增殖</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>结论：细胞周期蛋白D-CDK4中的一个新型二硫键充当快速开关，抑制激酶活性并阻止细胞增殖。这种氧化修饰形成于关键的半胱氨酸残基，这是CDK4所独有的，为设计预计对 PH 有益的选择性共价抑制剂。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 11 月 13 日。doi：10.1161/CIRCRESAHA.122.321836。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：肺动脉高压（PH）是一种慢性血管疾病，其特征包括平滑肌细胞过度增殖以及细胞氧化还原和代谢平衡紊乱。氧化剂诱导细胞周期停滞以停止增殖；然而，人们对氧化还原和代谢平衡知之甚少。在这里，我们报道了细胞周期蛋白 D-CDK4（细胞周期蛋白依赖性激酶 4）中的一种新型激酶抑制性二硫键，并研究了其在细胞增殖和 PH 中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在人肺动脉平滑肌细胞和人肺动脉内皮细胞中检测到细胞周期蛋白 D-CDK4 的氧化修饰。定点突变、串联质谱、基于细胞的实验、体外激酶活性测定、计算机结构模型，并利用一种新型氧化还原死亡组成型敲入小鼠来研究 CDK4 半胱氨酸修饰的性质并明确确定其在肺血管细胞增殖中的重要性。此外，在肺血管细胞中体内评估了细胞周期蛋白 D-CDK4 氧化。肺动脉高压患者和 3 个临床前 PH 模型中的动脉和分离的人肺动脉平滑肌细胞。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在体外细胞和体内肺动脉中，细胞周期蛋白 D-CDK4 分别在 C7/8 和 C135 之间形成可逆的氧化剂诱导的异二聚二硫二聚体，从而抑制细胞周期蛋白 D-CDK4 激酶活性，降低 Rb（视网膜母细胞瘤）蛋白磷酸化，并诱导细胞周期停滞。CDK4 C135 突变导致激酶受损表型，在实验性小鼠 PH 模型中降低细胞增殖率并减轻疾病表型，表明该半胱氨酸对于细胞周期蛋白 D-CDK4 激酶活性是不可或缺的。肺动脉高压患者的动脉和人肺动脉平滑肌细胞显示 CDK4 二硫化物水平降低，这与 CDK4 在人肺动脉高压中过度活跃一致。此外，金诺芬治疗可诱导细胞周期蛋白 D-CDK4 二硫化物，从而减轻疾病严重程度在实验性 PH 模型中通过减轻肺血管重塑。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：细胞周期蛋白D-CDK4中的一个新型二硫键充当快速开关，抑制激酶活性并阻止细胞增殖。这种氧化修饰形成于关键的半胱氨酸残基，这是CDK4所独有的，为设计预计对 PH 有益的选择性共价抑制剂。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37955182</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.122.321836>10.1161/CIRCRESAHA.122.321836</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955182</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>汉娜·奈特</dc:creator><dc:creator>吉安卡洛·阿比斯</dc:creator><dc:creator>曼普里特·考尔</dc:creator><dc:creator>汉娜·LH·格林</dc:creator><dc:creator>苏珊·克拉斯曼</dc:creator><dc:creator>克里斯汀·哈特曼</dc:creator><dc:creator>史蒂文·林纳姆</dc:creator><dc:creator>詹姆斯·克拉克</dc:creator><dc:creator>赵兰</dc:creator><dc:creator>克莱门斯·鲁珀特</dc:creator><dc:creator>阿斯特丽德·韦斯</dc:creator><dc:creator>拉尔夫·T·谢尔穆利</dc:creator><dc:creator>菲利普·伊顿</dc:creator><dc:creator>奥琳娜·鲁迪克</dc:creator><dc:date>2023-11-13</dc:date><dc:source>流通研究</dc:source><dc:title>细胞周期蛋白 D-CDK4 二硫键减弱肺血管细胞增殖</dc:title><dc:identifier>下午:37955182</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.321836</dc:identifier></item><item><title> DWORF 通过减少异常肌浆网簇延长 PLN-R14del 心肌病小鼠模型的寿命</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>结论：紊乱的 S/ER 是人类和小鼠 PLN-R14del 心肌病的主要特征，并导致心肌细胞死亡。DWORF 过表达通过减少异常现象，延缓了 R14^(Δ/Δ) 小鼠 PLN-R14del 心肌病的进展并延长了寿命。 S/ER 集群。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 11 月 13 日。doi：10.1161/CIRCRESAHA.123.323304。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景： <i>PLN</i> （受磷蛋白）基因的 p.Arg14del 变异会引起心肌病，导致严重的心力衰竭。钙处理缺陷和核周 PLN 聚集都被认为是这种疾病的病理驱动因素。矮人开放阅读框（DWORF）已被认为是导致这种疾病的病理因素。显示可以抵消肌浆/内质网 (S/ER) 中的 PLN 调节钙处理功能。在这里，我们研究了 DWORF 在这种心肌病中的潜在疾病调节作用及其对钙处理和 PLN 聚集的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们研究了 PLN-R14del 小鼠模型，该模型会发展出与人类患者具有相似特征的心肌病，并探讨心脏 DWORF 过度表达是否可以延缓心脏恶化。为此，携带 DWORF 的 R14 <sup>Δ/Δ</sup> （纯合子 PLN-R14del）小鼠使用转基因（R14 <sup>Δ/Δ</sup> DWORF <sup>Tg</sup> [带有 DWORF 转基因副本的 R14 <sup>Δ/Δ</sup>小鼠]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患有严重心力衰竭的 R14 <sup>Δ/Δ</sup>小鼠心脏中 DWORF 表达受到抑制。R14 <sup>Δ/Δ</sup>小鼠中恢复 DWORF 表达可延缓心脏纤维化和心力衰竭，并使寿命延长 2 倍以上（8 至 18 周） DWORF 加速野生型 PLN 离体心肌细胞的肌浆网钙重摄取和舒张，但在 R14 <sup>Δ/Δ</sup>心肌细胞中，肌浆网钙重摄取和舒张已经增强，并且 R14 <sup>Δ/Δ</sup>和 R14 <sup>Δ/ Δ</sup>之间没有检测到差异DWORF <sup>Tg</sup> 。相反，DWORF 过度表达延迟了大型致病性核周 PLN 簇的出现和形成。仔细检查发现，R14 <sup>Δ/Δ</sup>小鼠和人 p.Arg14del PLN 心脏组织中肌浆网标记与这些 PLN 簇共定位，因此这些以前称为聚集体由异常组织的 S/ER 组成。PLN-R14del 心肌病中的这种异常 S/ER 组织会导致心肌细胞丢失和替代性纤维化，从而导致心脏功能障碍。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：紊乱的 S/ER 是人类和小鼠 PLN-R14del 心肌病的主要特征，并导致心肌细胞死亡。DWORF 过表达通过减少异常的 S/ER 延迟了 R14 <sup>Δ/Δ</sup>小鼠的 PLN-R14del 心肌病进展并延长了寿命集群。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37955153</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323304>10.1161/CIRCRESAHA.123.323304</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955153</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>尼恩克·M·斯泰格</dc:creator><dc:creator>蒂姆·艾根拉姆</dc:creator><dc:creator>维维安·奥利维拉·努涅斯·特谢拉</dc:creator><dc:creator>安娜·M·费林加</dc:creator><dc:creator>伊丽莎白·M·舒腾</dc:creator><dc:creator>迪德里克·WD·库斯特</dc:creator><dc:creator>乔兰达·范德维尔登</dc:creator><dc:creator>阿努克·HG·沃尔特斯</dc:creator><dc:creator>本·NG·吉普曼斯</dc:creator><dc:creator>凯瑟琳·马卡雷维奇</dc:creator><dc:creator>朗达·巴塞尔-杜比</dc:creator><dc:creator>埃里克·N·奥尔森</dc:creator><dc:creator>鲁道夫·德波尔</dc:creator><dc:creator>赫尔曼·HW·西尔杰</dc:creator><dc:date>2023-11-13</dc:date><dc:source>流通研究</dc:source><dc:title>DWORF 通过减少异常肌浆网簇延长 PLN-R14del 心肌病小鼠模型的寿命</dc:title><dc:identifier>下午：37955153</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323304</dc:identifier></item><item><title> NAT10 通过 ac4C 介导的转录组调控参与心脏重塑</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>结论：因此，我们的数据表明，调节表观转录组过程，例如通过 NAT10 调节 ac4C 乙酰化，可能是对抗心脏重构的有前景的治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 11 月 13 日。doi：10.1161/CIRCRESAHA.122.322244。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：以心脏重塑为特征的心力衰竭与异常的表观遗传过程和异常的基因表达有关。在此，我们旨在阐明NAT10（N-乙酰转移酶10）介导的N4-乙酰胞苷（ac4C）乙酰化在心脏过程中的作用和机制。重塑。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过多种检测在患有心脏重构的人类和小鼠受试者中检测到 NAT10 和 ac4C 表达。随后，乙酰化 RNA 免疫沉淀和测序、用于 RNA 代谢测序的硫醇 (SH) 连接烷基化 (SLAM-seq) 和核糖体测序 (Ribo-seq) 用于阐明 ac4C 修饰的转录后调节在心脏重塑中的作用。此外，在接受 Ang II（血管紧张素 II）和横主动脉缩窄攻击的小鼠模型中进行了涉及 NAT10 过表达或敲低的功能实验。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在体外和体内心脏重塑模型以及心脏肥大患者中，NAT10 表达和 RNA ac4C 水平均升高。沉默和抑制 NAT10 可减弱 Ang II 诱导的心肌细胞肥大和心成纤维细胞活化。下一代测序显示 ac4C小鼠和人类心脏肥大的变化与整体 mRNA 丰度、稳定性和翻译效率的变化有关。从机制上讲，NAT10 可以通过上调<i>CD47</i>和<i>ROCK2</i>转录本的 mRNA ac4C 修饰来增强其稳定性和翻译效率，从而导致此外，Remodelin（一种 NAT10 抑制剂）已被证明可以通过抑制心脏纤维化、肥大和炎症反应来预防横主动脉缩窄小鼠的心脏功能损伤，同时还可以调节CD47 和 ROCK2 的表达水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：因此，我们的数据表明，调节表观转录组过程，例如通过 NAT10 调节 ac4C 乙酰化，可能是对抗心脏重构的有前景的治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37955115</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.122.322244>10.1161/CIRCRESAHA.122.322244</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955115</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>静石</dc:creator><dc:creator>杨传熙</dc:creator><dc:creator>赵坤</dc:creator><dc:creator>张静</dc:creator><dc:creator>彭丽</dc:creator><dc:creator>孔垂玉</dc:creator><dc:creator>吴晓光</dc:creator><dc:creator>孙浩良</dc:creator><dc:creator>郑锐</dc:creator><dc:creator>孙伟</dc:creator><dc:creator>陈连民</dc:creator><dc:creator>孔祥庆</dc:creator><dc:date>2023-11-13</dc:date><dc:source>流通研究</dc:source><dc:title>NAT10 通过 ac4C 介导的转录组调控参与心脏重塑</dc:title><dc:identifier>下午：37955115</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322244</dc:identifier></item><item><title>与常规治疗相比，SGLT2 抑制剂、GLP-1 受体激动剂和非类固醇 MRA 联合治疗对 2 型糖尿病和蛋白尿患者的估计终生心血管、肾脏和死亡率益处</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952217/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>背景：钠葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i)、胰高血糖素样肽 1 受体激动剂 (GLP-1 RA) 和非类固醇盐皮质激素受体拮抗剂 (MRA) Finerenone 均可单独降低心血管、肾脏和死亡率结果。患有 2 型糖尿病和蛋白尿的患者。然而，这些药物联合治疗的终生益处尚不清楚。方法：我们使用了 2 项 SGLT2i 试验（CANVAS 和 CREDENCE）、2 项非类固醇 MRA 试验的数据…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.067584。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>钠葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i)、胰高血糖素样肽 1 受体激动剂 (GLP-1 RA) 和非类固醇盐皮质激素受体拮抗剂 (MRA) Finerenone 均可单独降低心血管、肾脏和死亡率结果。患有 2 型糖尿病和白蛋白尿的患者。然而，这些药物联合治疗的终生获益尚不清楚。<b>方法：</b>我们使用了 2 项 SGLT2i 试验（CANVAS 和 CREDENCE）、2 项非类固醇 MRA 试验（FIDELIO-DKD 和 FigARO）的数据-DKD）和 8 个 GLP-1 RA 试验，评估联合治疗与传统治疗（肾素-血管紧张素系统阻断和传统危险因素控制）对心血管、肾脏和死亡率结果的相对影响。然后使用精算方法，我们估计了绝对风险SGLT2i、GLP-1 RA 和非甾体 MRA 联合治疗可减少 2 型糖尿病患者的病情，并通过对接受常规护理的参与者应用估计的联合治疗效果，至少适度增加白蛋白尿（尿白蛋白：肌酐比≥30 mg/g） CANVAS 和 CREDENCE<b>结果：</b>与传统治疗相比，SGLT2i、GLP-1 RA 和非类固醇 MRA 联合治疗与主要不良心血管事件 (MACE；非致命性心肌梗死) 的风险比为 0.65 (95% CI 0.55-0.76)。 ），非致命性中风或心血管死亡）。3 年内相应的估计绝对风险降低为 4.4% (95% CI 3.0-5.7)，需要治疗的人数为 23 (95% CI 18-33)。50开始联合治疗的 1 岁儿童，预计无 MACE 事件生存期为 21.1 年，而传统治疗为 17.9 年（延长了 3.2 年，95% CI 2.1-4.3）。预计无住院心力衰竭的生存期也会增加（ 3.2 年，95% CI 2.4-4.0）、CKD 进展（5.5 年，95% CI 4.0-6.7）、心血管死亡（2.2 年，95% CI 1.2-3.0）和全因死亡（2.4 年，95% CI） 1.4-3.4). 在假设联合治疗有 50% 附加效应的分析中，观察到无事件生存期的减弱但临床相关的增益，包括 MACE（2.4 年，95% CI 1.1-3.5）、CKD 进展（4.5 年，95 % CI 2.8-5.9),) 和全因死亡（1.8 年，95% CI 0.7-2.8）。<b>结论：</b>对于蛋白尿至少中度增加的 2 型糖尿病患者，联合治疗 SGLT2i、GLP-1 RA 和非类固醇 MRA 有可能在心血管和肾脏无事件生存率以及总体生存率方面带来相关收益。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952217/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37952217</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067584>10.1161/循环AHA.123.067584</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952217</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>布伦登·诺伊恩</dc:creator><dc:creator>希多·JL·赫尔斯平克</dc:creator><dc:creator>普里亚·瓦尔特</dc:creator><dc:creator>布赖恩·L·克拉吉特</dc:creator><dc:creator>罗伯特·弗莱彻</dc:creator><dc:creator>克莱尔·阿诺特</dc:creator><dc:creator>朱莉安娜·德·奥利维拉·科斯塔</dc:creator><dc:creator>迈克尔·奥·法尔斯特</dc:creator><dc:creator>萨莉-安妮·皮尔森</dc:creator><dc:creator>肯尼思·W·马哈菲</dc:creator><dc:creator>布鲁斯·尼尔</dc:creator><dc:creator>拉吉夫·阿加瓦尔</dc:creator><dc:creator>乔治·巴克里斯</dc:creator><dc:creator>弗拉多·佩尔科维奇</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>与常规治疗相比，SGLT2 抑制剂、GLP-1 受体激动剂和非类固醇 MRA 联合治疗对 2 型糖尿病和蛋白尿患者的估计终生心血管、肾脏和死亡率益处</dc:title><dc:identifier>下午:37952217</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067584</dc:identifier></item><item><title>不确定潜力的克隆造血可预测心律失常的发生</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>结论：CHIP 可能是心律失常的一个新的危险因素，表明它是心律失常预防和治疗的潜在调节目标。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 11 日：ehad670。doi：10.1093/eurheartj/ehad670。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：不确定潜能克隆造血 (CHIP) 是具有白血病前期突变的血细胞与年龄相关的扩张，与动脉粥样硬化性心血管疾病和心力衰竭相关。本研究旨在测试 CHIP 与新发心律失常的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：纳入没有普遍心律失常的英国生物银行参与者。共同主要研究结果是室上性心律失常、缓慢性心律失常和室性心律失常。次要结果是心脏骤停、心房颤动和任何心律失常。任何 CHIP [变异等位基因分数 (VAF)] 的关联使用多变量调整的 Cox 回归评估 CHIP 与心肌间质纤维化的关联 [使用心脏磁共振 (CMR) 测量 T1]也进行了测试。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：本研究包括 410 702 名参与者 [CHIP：n = 13 892 (3.4%)；大型 CHIP：n = 9191 (2.2%)]。任何大型 CHIP 均与 1.11 的多变量调整风险比相关 [95室上性心律失常的%置信区间 (CI) 1.04-1.18；P = .001] 和 1.13 (95% CI 1.05-1.22；P = .001)，1.09 (95% CI 1.01-1.19；P = .031) 和 1.13缓慢性心律失常为 (95% CI 1.03-1.25；P = .011)，室性心律失常为 1.16 (95% CI 1.00-1.34；P = .049) 和 1.22 (95% CI 1.03-1.45；P = .021)分别。关联与冠状动脉疾病和心力衰竭无关。心律失常亚型之间的关联也存在异质性，并且与心脏骤停的关联最强。基因特异性分析显示除 DNMT3A 之外的驱动基因之间的心律失常风险增加。大 CHIP 与 1.31 相关根据 CMR 检测，处于心肌纤维化前五分位的几率 (95% CI 1.07-1.59；P = .009)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：CHIP 可能是心律失常的一个新的危险因素，表明它是心律失常预防和治疗的潜在调节目标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37952204</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad670>10.1093/eurheartj/ehad670</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952204</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>阿特·舒尔曼斯</dc:creator><dc:creator>凯特琳·弗拉斯哈特</dc:creator><dc:creator>维克多·诺法尔</dc:creator><dc:creator>苏美杰玛·曹</dc:creator><dc:creator>麦斯巴·乌丁</dc:creator><dc:creator>中尾哲志</dc:creator><dc:creator>阿布舍克·尼鲁拉</dc:creator><dc:creator>马库斯·克拉奎斯特博士</dc:creator><dc:creator>拉谢尔·D·周</dc:creator><dc:creator>艾米·林</dc:creator><dc:creator>赛义德·穆罕默德·萨达塔加</dc:creator><dc:creator>金兰纳里</dc:creator><dc:creator>黄梅根</dc:creator><dc:creator>惠特尼霍恩斯比</dc:creator><dc:creator>史蒂文·卢比茨</dc:creator><dc:creator>克里斯蒂·巴兰坦</dc:creator><dc:creator>悉达多贾斯瓦尔</dc:creator><dc:creator>彼得·利比</dc:creator><dc:creator>本杰明·艾伯特</dc:creator><dc:creator>亚历山大·G·比克</dc:creator><dc:creator>帕特里克·埃利诺</dc:creator><dc:creator>普拉迪普·纳塔拉詹</dc:creator><dc:creator>迈克尔·C·霍尼伯格</dc:creator><dc:date>2023-11-12</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>不确定潜力的克隆造血可预测心律失常的发生</dc:title><dc:identifier>下午:37952204</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad670</dc:identifier></item><item><title>袋阀面罩通气和院外心脏骤停的生存率：一项多中心研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>背景：很少有研究在气道放置前的早期心肺复苏 (CPR) 过程中测量通气量。复苏指南建议每 30 次胸外按压后暂停一次以提供通气。胸外按压提前暂停期间提供的气囊-瓣膜-面罩通气的有效性尚不清楚我们试图确定：(1) 30:2 心肺复苏过程中球囊-瓣膜-面罩通气导致肺充气的发生率；(2) 通气与……的关联</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.065561。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>很少有研究在气道放置前的早期心肺复苏 (CPR) 过程中测量通气量。复苏指南建议每 30 次胸外按压后暂停一次以提供通气。胸外按压提前暂停期间提供的气囊-瓣膜-面罩通气的有效性尚不清楚我们试图确定：(1) 30:2 心肺复苏过程中使用球囊-瓣膜-面罩通气时肺充气的发生率；(2) 通气与院外心脏骤停后结果的关系。<b>方法：</b>我们研究了患者复苏结果联盟 CCC 研究（在院外心脏骤停患者中进行连续按压与标准心肺复苏试验）的 6 个地点的院外心脏骤停患者。我们分析了分配到 30:2 CPR 组的患者，用心脏除颤器/监护仪记录≥2分钟的胸部生物阻抗信号。可检测的通气波形被定义为生物阻抗幅度≥0.5Ω（对应于≥250mL V <sub>T</sub> ）和持续时间≥1秒。我们定义了胸外按压暂停作为胸外按压 3 至 15 秒的中断。我们比较了 2 组的通气发生率和结果：通气波形出现 &lt;50% 暂停的患者（第 1 组）与波形出现 ≥50% 暂停的患者（第 1 组）第 2 组).<b>结果：</b> 1976 名患者中，平均年龄为 65 岁；66% 为男性。从开始胸外按压到高级气道放置，30:2 CPR 的平均±SD 持续时间为 9.8±4.9 分钟。在此期间，我们确定了 26861 次胸外按压暂停；60% 的患者在 &lt;50% 的暂停中出现通气波形（第 1 组，n=1177），40% 在 ≥50% 的暂停中出现通气波形（第 2 组，n= 799） ）。第 1 组每位患者平均有 12 次暂停和 2 次通气，而第 2 组每位患者有 12 次暂停和 12 次通气。第 2 组的院前自主循环恢复率较高（40.7% 对比 25.2%； <i>P</i> &lt; 0.0001） ）、出院生存率（13.5% 对比 4.1%； <i>P</i> &lt;0.0001）以及神经系统预后良好的生存率（10.6% 对比 2.4%； <i>P</i> &lt;0.0001）。在调整混杂因素后，这些关联仍然存在。<b>结论：</b>在这项研究中，在 30:2 心肺复苏过程中，气囊-瓣膜-面罩通气很少发生肺充气。≥50% 的暂停时间中，肺充气与自主循环恢复改善、生存以及具有良好神经学结果的生存相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37952192</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065561>10.1161/CIRCULATIONAHA.123.065561</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952192</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>艾哈迈德·H·伊德里斯</dc:creator><dc:creator>伊丽莎白·阿拉门迪·埃塞纳罗</dc:creator><dc:creator>布赖恩·勒鲁</dc:creator><dc:creator>哈比尔·贾雷吉贝蒂亚</dc:creator><dc:creator>杨贝蒂</dc:creator><dc:creator>莎拉·谢弗</dc:creator><dc:creator>玛丽·P·张</dc:creator><dc:creator>汤姆·雷</dc:creator><dc:creator>彼得·库登丘克</dc:creator><dc:creator>吉姆·克里斯滕森</dc:creator><dc:creator>克里斯蒂安·瓦扬古</dc:creator><dc:creator>克利夫顿·W·卡拉威</dc:creator><dc:creator>大卫·萨尔西多</dc:creator><dc:creator>乔纳斯·卡森</dc:creator><dc:creator>詹妮弗·布莱克伍德</dc:creator><dc:creator>亨利·王</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>袋阀面罩通气和院外心脏骤停的生存率：一项多中心研究</dc:title><dc:identifier>下午:37952192</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065561</dc:identifier></item><item><title>直接口服抗凝剂预防设备检测到的心房颤动患者中风：NOAH-AFNET 6 和 ARTESiA 试验的研究级荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>背景：设备检测到的心房颤动 (AF)（也称为亚临床 AF 或心房高频率发作）是植入心律设备患者的常见症状，并且与缺血性中风风险增加相关。口服抗凝药物是否有效方法：我们对 MEDLINE 和 Embase 进行了系统评价，以进行随机试验，比较口服抗凝剂与抗血小板药物或不进行抗血栓治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.067512。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>设备检测到的心房颤动 (AF)（也称为亚临床 AF 或心房高频率发作）是植入心律设备患者的常见症状，并且与缺血性中风风险增加相关。口服抗凝药物是否有效<b>方法：</b>我们对 MEDLINE 和 Embase 进行了系统评价，以进行随机试验，比较口服抗凝剂与抗血小板药物或不进行抗血栓治疗的成人患者，这些患者患有由起搏器、植入式心脏复律除颤器记录的设备检测到的房颤，心脏再同步治疗装置或植入式心脏监护仪。我们使用随机效应模型进行荟萃分析，并使用 GRADE 框架对证据质量进行评级。该评论是预先注册的 (PROSPERO CRD42023463212)。<b>结果：</b>从 785 个独特的引用中，我们确定了两项具有相关临床结果数据的随机试验；NOAH-AFNET 6（2,536 名受试者）评估了艾多沙班，ARTESiA（4,012 名受试者）评估了阿哌沙班。荟萃分析表明，口服抗凝药物可减少缺血性中风（相对风险 [RR] 0.68, 95） ％置信区间[CI] 0.50-0.92；高质量证据）。两项试验的结果是一致的（异质性的 I <sup>2</sup>统计=0%）。口服抗凝药还减少了心血管死亡、全因中风、外周动脉栓塞、心肌梗死或肺栓塞（RR 0.85，95% CI 0.73-1.00，I <sup>2</sup> =0%；中等质量证据）。心血管死亡没有减少（RR 0.95，95% CI 0.76-1.17， I <sup>2</sup> =0%；中等质量证据）或全因死亡率（RR 1.08，95% CI 0.96-1.21 I <sup>2</sup> =0%；中等质量证据）。口服抗凝药增加大出血（RR 1.62，95% CI 1.05-2.5 <sup>I²</sup> =61%；高质量证据）。<b>结论：</b> NOAH-AFNET 6 和 ARTESiA 试验的结果相互一致。这两个大型随机试验的荟萃分析提供了口服抗凝药物的高质量证据与艾多沙班或阿哌沙班联合使用可降低设备检测到的 AF 患者中风的风险，并增加大出血的风险。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37952187</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067512>10.1161/循环AHA.123.067512</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952187</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>威廉·F·麦金太尔</dc:creator><dc:creator>亚历山大·本茨</dc:creator><dc:creator>尼娜·贝歇尔</dc:creator><dc:creator>杰弗里·希利</dc:creator><dc:creator>克里斯托弗·B·格兰杰</dc:creator><dc:creator>莉娜·里瓦德</dc:creator><dc:creator>约翰·卡姆</dc:creator><dc:creator>安德烈亚斯·戈特</dc:creator><dc:creator>安东尼娅·扎普夫</dc:creator><dc:creator>马可·阿林斯</dc:creator><dc:creator>斯图尔特·J·康诺利</dc:creator><dc:creator>保卢斯·基希霍夫</dc:creator><dc:creator>雷纳托·D·洛佩斯</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>直接口服抗凝剂预防设备检测到的心房颤动患者中风：NOAH-AFNET 6 和 ARTESiA 试验的研究级荟萃分析</dc:title><dc:identifier>下午：37952187</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067512</dc:identifier></item><item><title>索马鲁肽对射血分数保留且肥胖的心力衰竭患者的症状、功能和生活质量的影响：STEP-HFpEF 试验的预设分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>背景：射血分数保留 (HFpEF) 和肥胖的心力衰竭 (HF) 患者的症状和功能障碍负担较重，生活质量较差。在 STEP-HFpEF 试验中，每周一次 2.4 mg 索马鲁肽可改善症状，身体限制和运动功能，并减少炎症和体重。这项预先指定的分析研究了索马鲁肽对堪萨斯州范围内主要和验证性次要终点的影响…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 12 日。doi：10.1161/CIRCULATIONAHA.123.067505。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>射血分数保留 (HFpEF) 和肥胖的心力衰竭 (HF) 患者的症状和功能障碍负担较重，生活质量较差。在 STEP-HFpEF 试验中，每周一次 2.4 mg 索马鲁肽可改善症状，这项预先指定的分析调查了索马鲁肽对堪萨斯城心肌病问卷 (KCCQ) 基线评分范围内的主要和验证性次要终点的影响；以及对所有关键总结和体重的影响。<b>方法：</b> STEP-HFpEF 将 529 名有症状的 HF、EF ≥ 45% 和 BMI ≥ 30 kg/m <sup>2</sup>的参与者随机分配至每周一次的索马鲁肽 2.4 mg 或安慰剂，持续 52 周。双重主要终点是 KCCQ- 的变化临床总结评分 (CSS) 和体重。确认性次要终点包括 6 分钟步行距离 (6MWD) 的变化、分层复合终点（死亡、心力衰竭事件以及 KCCQ-CSS 和 6MWD 的变化）以及 C-变化患者在基线时按 KCCQ-CSS 三分位数进行分层。在这些亚组中检查了索马鲁肽对主要、确认性次要和选择探索性终点 (NTproBNP) 的影响。索马鲁肽对其他 KCCQ 领域的影响（总症状评分 [包括症状负担和结果<b>：</b>三分位数的基线中位 KCCQ-CSS 分别为 37、59 和 77 分。索马鲁肽持续改善 KCCQ 三分位数 1-3 的主要终点（估计治疗差异 (ETD;95% CI)：对于 KCCQ-CSS，10.7 (5.4 ,16.1), 8.1 (2.7,13.4), 4.6 (-0.6,9.9) 分；对于体重， - 11 (-13.2,-8.8), -9.4 (-11.5,-7.2), -11.8 (-14.0, -9.6)%，分别；P<i>相互作用</i>= 0.28 和 0.29，分别）；对于确认性次要和探索性终点也观察到相同的情况（所有 P<i>相互作用</i>>;0.1）。接受索马鲁肽治疗的患者在所有关键 KCCQ 领域都经历过这种情况（ETD：6.7）跨改善领域为 -9.6 分；所有<i>P</i> ≤ 0.001）。与安慰剂治疗患者相比，接受索马鲁肽治疗的患者在所有 KCCQ 领域中经历了至少 5、10、15 和 20 分的改善（优势比：1.6- 2.9 跨领域； <i>P</i> &lt; 0.05）。<b>结论：</b>在 HFpEF 和肥胖患者中，无论基线健康状况如何，索马鲁肽都能显着改善 HF 相关症状、身体限制、运动功能、炎症、体重和 NTproBNP。索马鲁肽扩展到所有关键的 KCCQ 领域。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37952180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37952180</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067505>10.1161/CIRCULATIONAHA.123.067505</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37952180</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>苏博德·维尔玛</dc:creator><dc:creator>巴里·博洛格</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>梅兰妮·J·戴维斯</dc:creator><dc:creator>托马斯·乔恩·詹森</dc:creator><dc:creator>索伦·拉斯穆森</dc:creator><dc:creator>彼得·埃尔兰·马斯特兰德</dc:creator><dc:creator>马克·皮特里</dc:creator><dc:creator>桑吉夫·J·沙阿</dc:creator><dc:creator>伊藤浩</dc:creator><dc:creator>莫滕·舒</dc:creator><dc:creator>沃伊捷赫·梅列诺夫斯基</dc:creator><dc:creator>沃尔特·阿巴亚拉特纳</dc:creator><dc:creator>达兰·W·基茨曼</dc:creator><dc:date>2023-11-12</dc:date><dc:source>循环</dc:source><dc:title>索马鲁肽对射血分数保留且肥胖的心力衰竭患者的症状、功能和生活质量的影响：STEP-HFpEF 试验的预设分析</dc:title><dc:identifier>下午:37952180</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067505</dc:identifier></item><item><title>射血分数轻度降低或保留的心力衰竭患者使用达格列净后估计肾小球滤过率下降：DELIVER 随机临床试验的预先指定二次分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37952176/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113071535&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在接受达格列净治疗的 HFmrEF 或 HFpEF 患者中，初始 eGFR 下降很常见，但与随后的心血管或肾脏事件风险无关。这些数据强化了临床指导，即不应因初始 eGFR 下降而中断或终止 SGLT2is。 eGFR 下降。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 11 月 12 日。doi：10.1001/jamacardio.2023.4664。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: An initial decline in estimated glomerular filtration rate (eGFR) is expected after initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed across patients with diabetes, chronic kidney disease, and heart failure. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To examine the implications of initial changes in eGFR among patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis of the results of the DELIVER randomized clinical trial, which was an international multicenter study of patients with EF greater than 40% and eGFR greater than or equal to 25. The DELIVER trial took place from August 2018 to March 2022. Data for the current prespecified study were analyzed from February to October 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTERVENTION: Dapagliflozin, 10 mg per day, or placebo. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: In this prespecified analysis, the frequency of an initial eGFR decline (baseline to month 1) was compared between dapagliflozin and placebo. Cox models adjusted for baseline eGFR and established prognostic factors were fit to estimate the association of an initial eGFR decline with cardiovascular (cardiovascular death or heart failure event) and kidney (≥50% eGFR decline, eGFR&lt;15 or dialysis, death from kidney causes) outcomes, landmarked at month 1, stratified by diabetes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Study data from 5788 participants (mean [SD] age, 72 [10] years; 3253 male [56%]) were analyzed. The median (IQR) change in eGFR level from baseline to month 1 was -1 (-6 to 5) with placebo and -4 (-9 to 1) with dapagliflozin (difference, -3; P &lt; .001). A higher proportion of patients assigned to dapagliflozin developed an initial eGFR decline greater than 10% vs placebo (1144 of 2892 [40%] vs 737 of 2896 [25%]; odds ratio, 1.9; 95% CI, 1.7-2.1; P difference &lt;.001). An initial eGFR decline of greater than 10% (vs ≤10%) was associated with a higher risk of the primary cardiovascular outcome among those randomized to placebo (adjusted hazard ratio [aHR], 1.33; 95% CI, 1.10-1.62) but not among those randomized to dapagliflozin (aHR, 0.90; 95% CI, 0.74-1.09; P for interaction = .01). Similar associations were observed when alternative thresholds of initial eGFR decline were considered and when analyzed as a continuous measure. An initial eGFR decline of greater than 10% was not associated with adverse subsequent kidney composite outcomes in dapagliflozin-treated patients (aHR, 0.94; 95% CI, 0.49-1.82). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: Among patients with HFmrEF or HFpEF treated with dapagliflozin, an initial eGFR decline was frequent but not associated with subsequent risk of cardiovascular or kidney events. These data reinforce clinical guidance that SGLT2is should not be interrupted or discontinued in response to an initial eGFR decline. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37952176/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37952176</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4664>10.1001/jamacardio.2023.4664</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37952176</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Finnian R Mc Causland</dc:creator><dc:creator> Brian L Claggett</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:creator> Akshay Desai</dc:creator><dc:creator> Pardeep Jhund</dc:creator><dc:creator> Orly Vardeny</dc:creator><dc:creator> James C Fang</dc:creator><dc:creator> Rudolf A de Boer</dc:creator><dc:creator> Kieran F Docherty</dc:creator><dc:creator> Adrian F Hernandez</dc:creator><dc:creator> Silvio E Inzucchi</dc:creator><dc:creator> Mikhail N Kosiborod</dc:creator><dc:creator> Carolyn SP Lam</dc:creator><dc:creator> Felipe Martinez</dc:creator><dc:creator> Jose F Kerr Saraiva</dc:creator><dc:creator> Martina M McGrath</dc:creator><dc:creator> Sanjiv J Shah</dc:creator><dc:creator> Subodh Verma</dc:creator><dc:creator> Anna Maria Langkilde</dc:creator><dc:creator> Magnus Petersson</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:date> 2023-11-12</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial</dc:title><dc:identifier> pmid:37952176</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4664</dc:identifier></item><item><title> Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States</title><link/> https://pubmed.ncbi.nlm.nih.gov/37952173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: There was an alarming increase in cardiovascular hospitalizations among younger adults in the US from 2008 to 2019, and disparities between those residing in low- and higher-income communities did not narrow. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 11:ehad772. doi: 10.1093/eurheartj/ehad772. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Declines in cardiovascular mortality have stagnated in the United States since 2011. There is growing concern that these patterns reflect worsening cardiovascular health in younger adults. However, little is known about how the burden of acute cardiovascular hospitalizations and mortality have changed in this population. Changes in cardiovascular hospitalizations and mortality among adults aged 25-64 years were evaluated, overall and by community-level income. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Using the National Inpatient Sample, age-standardized annual hospitalization and inhospital mortality rates for acute myocardial infarction (AMI), heart failure, and ischemic stroke were determined among adults aged 25-64 years. Quasi-Poisson and quasi-binominal regression models were fitted to compare outcomes between individuals residing in low- and higher-income communities. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Between 2008 and 2019, age-standardized hospitalization rates for AMI increased among younger adults from 155.0 (95% CI 154.6, 155.4) per 100,000 to 160.7 (160.3, 161.1) per 100,000 (absolute change +5.7 [5.0, 6.3], p&lt;0.001). Heart failure hospitalizations also increased (165.3 [164.8, 165.7] to 225.3 [224.8, 225.8], absolute change +60.0 (59.3, 60.6), p&lt;0.001), as ischemic stroke hospitalizations (76.3 [76.1, 76.7] to 108.1 [107.8, 108.5], absolute change +31.7 (31.2, 32.2), p&lt;0.001). Across all conditions, hospitalizations rates were significantly higher among younger adults residing in low-income compared with higher-income communities, and disparities did not narrow between groups. In-hospital mortality decreased for all conditions over the study period. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: There was an alarming increase in cardiovascular hospitalizations among younger adults in the US from 2008 to 2019, and disparities between those residing in low- and higher-income communities did not narrow.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37952173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37952173</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad772>10.1093/eurheartj/ehad772</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37952173</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Chantal M Henry</dc:creator><dc:creator> Andrew S Oseran</dc:creator><dc:creator> ZhaoNian Zheng</dc:creator><dc:creator> Huaying Dong</dc:creator><dc:creator> Rishi K Wadhera</dc:creator><dc:date> 2023-11-12</dc:date><dc:source> European heart journal</dc:source><dc:title> Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States</dc:title><dc:identifier> pmid:37952173</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad772</dc:identifier></item><item><title> &#39;Hard and Fast&#39; Resuscitation Guidelines May Need a Bit of &#39;Breathing&#39; Room</title><link/> https://pubmed.ncbi.nlm.nih.gov/37952160/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.066071. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37952160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37952160</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066071>10.1161/CIRCULATIONAHA.123.066071</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37952160</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Michael Christopher Kurz</dc:creator><dc:date> 2023-11-12</dc:date><dc:source> Circulation</dc:source><dc:title> &#39;Hard and Fast&#39; Resuscitation Guidelines May Need a Bit of &#39;Breathing&#39; Room</dc:title><dc:identifier> pmid:37952160</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066071</dc:identifier></item><item><title> Germinal centers output clonally diverse plasma cell populations expressing high- and low-affinity antibodies</title><link/> https://pubmed.ncbi.nlm.nih.gov/37951212/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> Germinal centers (GCs) form in lymph nodes after immunization or infection to facilitate antibody affinity maturation and memory and plasma cell (PC) development. PC differentiation is thought to involve stringent selection for GC B cells expressing the highest-affinity antigen receptors, but how this plays out during complex polyclonal responses is unclear. We combine temporal lineage tracing with antibody characterization to gain a snapshot of PCs developing during influenza infection. GCs... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Nov 7:S0092-8674(23)01173-X. doi: 10.1016/j.cell.2023.10.022. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Germinal centers (GCs) form in lymph nodes after immunization or infection to facilitate antibody affinity maturation and memory and plasma cell (PC) development. PC differentiation is thought to involve stringent selection for GC B cells expressing the highest-affinity antigen receptors, but how this plays out during complex polyclonal responses is unclear. We combine temporal lineage tracing with antibody characterization to gain a snapshot of PCs developing during influenza infection. GCs co-mature B cell clones with antibody affinities spanning multiple orders of magnitude; however, each generates PCs with similar efficiencies, including weak binders. Within lineages, PC selection is not restricted to variants with the highest-affinity antibodies. Differentiation is commonly associated with proliferative expansion to produce &quot;nodes&quot; of identical PCs. Immunization-induced GCs generate fewer PCs but still of low- and high-antibody affinities. We propose that generating low-affinity antibody PCs reflects an evolutionary compromise to facilitate diverse serum antibody responses.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37951212/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37951212</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.10.022>10.1016/j.cell.2023.10.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37951212</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Adrien Sprumont</dc:creator><dc:creator> Ana Rodrigues</dc:creator><dc:creator> Simon J McGowan</dc:creator><dc:creator> Colin Bannard</dc:creator><dc:creator> Oliver Bannard</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> Cell</dc:source><dc:title> Germinal centers output clonally diverse plasma cell populations expressing high- and low-affinity antibodies</dc:title><dc:identifier> pmid:37951212</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.022</dc:identifier></item><item><title> A Complex Anterior Mediastinal Mass in a Young Adult</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950914/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067585. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950914/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950914</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067585>10.1161/CIRCULATIONAHA.123.067585</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950914</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Giselle Alexandra Suero-Abreu</dc:creator><dc:creator> Lily Sung</dc:creator><dc:creator> Anushri Parakh</dc:creator><dc:creator> Brian Ghoshhajra</dc:creator><dc:creator> Tomas G Neilan</dc:creator><dc:creator> Doreen DeFaria Yeh</dc:creator><dc:creator> Yin P Hung</dc:creator><dc:creator> Danielle B Cameron</dc:creator><dc:creator> Jordan P Bloom</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> Circulation</dc:source><dc:title> A Complex Anterior Mediastinal Mass in a Young Adult</dc:title><dc:identifier> pmid:37950914</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067585</dc:identifier></item><item><title> Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> Background: Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling. Methods: In this prospective, randomized, open-label, blinded endpoint trial, in a single... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067597. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling. <b>Methods:</b> In this prospective, randomized, open-label, blinded endpoint trial, in a single UK hospital, 220 women were randomly assigned 1:1 to self-monitoring with research physician-optimized antihypertensive titration, or usual postnatal care from primary care physician and midwife. Participants were aged 18 years or over, with pre-eclampsia or gestational hypertension, requiring antihypertensives on hospital discharge postnatally. Pre-specified secondary cardiac imaging outcomes were recorded by echocardiography around delivery, and again at blood pressure primary outcome assessment, around nine months postpartum, when cardiovascular magnetic resonance was also performed. <b>Results:</b> 187 women (101 intervention; 86 usual care) underwent echocardiography at baseline and follow up, at a mean 258+/-14.6 days postpartum, of which 174 (93 intervention; 81 usual care) also had cardiovascular magnetic resonance at follow up. Relative wall thickness by echocardiography was 0.06 (95% CI0.07 to 0.05, P=&lt;0.001) lower in the intervention group between baseline and follow up, and cardiovascular magnetic resonance at follow up demonstrated a lower left ventricular mass (-6.37g/m <sup>2</sup> (95% CI -7.99 to -4.74, P&lt;0.001), end diastolic volume (-3.87ml/m <sup>2</sup> , 95% CI -6.77 to -0.98, P=0.009) and end systolic volume (-3.25ml/m <sup>2</sup> , 95% CI 4.87 to -1.63, P &lt;0.001) and higher left and right ventricular ejection fraction by 2.6% (95% CI 1.3 to 3.9, P&lt;0.001) and 2.8% (95% CI 1.4 to 4.1, P&lt;0.001) respectively. Echocardiography assessed left ventricular diastolic function demonstrated a mean difference in average E/E&#39; of 0.52 (95% CI -0.97 to -0.07, P=0.024), and a reduction in left atrial volumes of -4.33ml/m <sup>2</sup> (95% CI -5.52 to -3.21, P=&lt;0.001) between baseline and follow up, when adjusted for baseline differences in measures. <b>Conclusions:</b> Short-term postnatal optimization of blood pressure control following hypertensive pregnancy, through self-monitoring and physician-guided antihypertensive titration, associates with long term changes in cardiovascular structure and function, in a pattern associated with more favorable cardiovascular outcomes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950907</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067597>10.1161/CIRCULATIONAHA.123.067597</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950907</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Jamie Kitt</dc:creator><dc:creator> Samuel Krasner</dc:creator><dc:creator> Logan Barr</dc:creator><dc:creator> Annabelle Frost</dc:creator><dc:creator> Katherine Tucker</dc:creator><dc:creator> Paul A Bateman</dc:creator><dc:creator> Katie Suriano</dc:creator><dc:creator> Yvonne Kenworthy</dc:creator><dc:creator> Winok Lapidaire</dc:creator><dc:creator> Miriam Lacharie</dc:creator><dc:creator> Rebecca Mills</dc:creator><dc:creator> Cristian Roman</dc:creator><dc:creator> Lucy Mackillop</dc:creator><dc:creator> Alexandra Cairns</dc:creator><dc:creator> Christina Aye</dc:creator><dc:creator> Vanessa Ferreira</dc:creator><dc:creator> Stefan Piechnik</dc:creator><dc:creator> Elena Lukaschuk</dc:creator><dc:creator> Basky Thilaganathan</dc:creator><dc:creator> Lucy C Chappell</dc:creator><dc:creator> Adam J Lewandowski</dc:creator><dc:creator> Richard J McManus</dc:creator><dc:creator> Paul Leeson</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> Circulation</dc:source><dc:title> Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study</dc:title><dc:identifier> pmid:37950907</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067597</dc:identifier></item><item><title> Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> Background: The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). Methods: Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high-risk for developing HF were identified using 1-step screening strategies: risk score... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). <b>Methods:</b> Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high-risk for developing HF were identified using 1-step screening strategies: risk score (WATCH-DM≥12); N-terminal pro-B-type natriuretic peptide (NT-proBNP;≥125 pg/mL); high-sensitivity cardiac troponin (hs-cTnT ≥14 ng/L, hs-cTnI≥31 ng/L); echocardiography-based diabetic cardiomyopathy (echo-DbCM; LA enlargement, LV hypertrophy, or diastolic dysfunction). High-risk participants were also identified using 2-step screening strategies with a second test to additionally identify residual risk among those deemed low-risk by the first test: WATCH-DM/NT-proBNP, NT-proBNP/hs-cTn, NT-proBNP/echo-DbCM. Across screening strategies, the proportion of HF events identified, 5-year number needed to treat (NNT <sup>5</sup> ) and number needed to screen (NNS <sup>5</sup> ) to prevent 1 HF event with an SGLT2i among high-risk participants, and cost of screening were estimated. <b>Results:</b> The initial study cohort included 6,293 participants (48.2% women), of which 77.7% without prevalent ASCVD were evaluated with different HF screening strategies. At 5-year follow-up, 6.2% of participants without ASCVD developed incident HF. The NNT <sup>5</sup> to prevent 1 HF event with an SGLT2i among participants without ASCVD was 43 (95%CI, 29-72). In the cohort without ASCVD, high-risk participants identified using 1-step screening strategies had low NNT <sup>5</sup> (22 for NT-proBNP to 37 for echo-DbCM). However, a substantial proportion of HF events occurred among participants identified as low-risk using 1-step screening approaches (29% for echo-DbCM to 47% for hs-cTn). 2-step screening strategies captured most HF events (75-89%) in the high-risk subgroup with a comparable NNT <sup>5</sup> as the 1-step screening approaches (30-32). The NNS <sup>5</sup> to prevent 1 HF event was similar across 2-step screening strategies (45-61). However, the number of tests and associated costs were lowest for WATCH-DM/NT-proBNP ($1,061) compared with other 2-step screening strategies (NT-proBNP/hs-cTn: $2,894; NT-proBNP/echo-DbCM: $16,358). <b>Conclusions:</b> Selective NT-proBNP testing based on the WATCH-DM score efficiently identified a high-risk primary prevention population with diabetes expected to derive marked absolute benefits from SGLT2i to prevent HF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950893</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067530>10.1161/CIRCULATIONAHA.123.067530</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950893</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Kershaw V Patel</dc:creator><dc:creator> Matthew W Segar</dc:creator><dc:creator> David C Klonoff</dc:creator><dc:creator> Muhammad Shahzeb Khan</dc:creator><dc:creator> Muhammad Shariq Usman</dc:creator><dc:creator> Carolyn SP Lam</dc:creator><dc:creator> Subodh Verma</dc:creator><dc:creator> Andrew P DeFilippis</dc:creator><dc:creator> Khurram Nasir</dc:creator><dc:creator> Stephan JL Bakker</dc:creator><dc:creator> B Daan Westenbrink</dc:creator><dc:creator> Robin PF Dullaart</dc:creator><dc:creator> Javed Butler</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:creator> Ambarish Pandey</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> Circulation</dc:source><dc:title> Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis</dc:title><dc:identifier> pmid:37950893</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067530</dc:identifier></item><item><title> Device-measured physical activity and cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS) consortium</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Compositional data analyses revealed a distinct hierarchy of behaviours. Moderate-vigorous physical activity demonstrated the strongest, most time-efficient protective associations with cardiometabolic outcomes. Theoretical benefits from reallocating SB into sleep, standing, or LIPA required substantial changes in daily activity. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 10:ehad717. doi: 10.1093/eurheartj/ehad717. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Physical inactivity, sedentary behaviour (SB), and inadequate sleep are key behavioural risk factors of cardiometabolic diseases. Each behaviour is mainly considered in isolation, despite clear behavioural and biological interdependencies. The aim of this study was to investigate associations of five-part movement compositions with adiposity and cardiometabolic biomarkers. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Cross-sectional data from six studies (n = 15 253 participants; five countries) from the Prospective Physical Activity, Sitting and Sleep consortium were analysed. Device-measured time spent in sleep, SB, standing, light-intensity physical activity (LIPA), and moderate-vigorous physical activity (MVPA) made up the composition. Outcomes included body mass index (BMI), waist circumference, HDL cholesterol, total:HDL cholesterol ratio, triglycerides, and glycated haemoglobin (HbA1c). Compositional linear regression examined associations between compositions and outcomes, including modelling time reallocation between behaviours. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The average daily composition of the sample (age: 53.7 ± 9.7 years; 54.7% female) was 7.7 h sleeping, 10.4 h sedentary, 3.1 h standing, 1.5 h LIPA, and 1.3 h MVPA. A greater MVPA proportion and smaller SB proportion were associated with better outcomes. Reallocating time from SB, standing, LIPA, or sleep into MVPA resulted in better scores across all outcomes. For example, replacing 30 min of SB, sleep, standing, or LIPA with MVPA was associated with -0.63 (95% confidence interval -0.48, -0.79), -0.43 (-0.25, -0.59), -0.40 (-0.25, -0.56), and -0.15 (0.05, -0.34) kg/m2 lower BMI, respectively. Greater relative standing time was beneficial, whereas sleep had a detrimental association when replacing LIPA/MVPA and positive association when replacing SB. The minimal displacement of any behaviour into MVPA for improved cardiometabolic health ranged from 3.8 (HbA1c) to 12.7 (triglycerides) min/day. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Compositional data analyses revealed a distinct hierarchy of behaviours. Moderate-vigorous physical activity demonstrated the strongest, most time-efficient protective associations with cardiometabolic outcomes. Theoretical benefits from reallocating SB into sleep, standing, or LIPA required substantial changes in daily activity.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950859</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad717>10.1093/eurheartj/ehad717</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950859</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Joanna M Blodgett</dc:creator><dc:creator> Matthew N Ahmadi</dc:creator><dc:creator> Andrew J Atkin</dc:creator><dc:creator> Sebastien Chastin</dc:creator><dc:creator> Hsiu-Wen Chan</dc:creator><dc:creator> Kristin Suorsa</dc:creator><dc:creator> Esmee A Bakker</dc:creator><dc:creator> Pasan Hettiarcachchi</dc:creator><dc:creator> Peter J Johansson</dc:creator><dc:creator> Lauren B Sherar</dc:creator><dc:creator> Vegar Rangul</dc:creator><dc:creator> Richard M Pulsford</dc:creator><dc:creator> Gita Mishra</dc:creator><dc:creator> Thijs MH Eijsvogels</dc:creator><dc:creator> Sari Stenholm</dc:creator><dc:creator> Alun D Hughes</dc:creator><dc:creator> Armando M Teixeira-Pinto</dc:creator><dc:creator> Ulf Ekelund</dc:creator><dc:creator> I Min Lee</dc:creator><dc:creator> Andreas Holtermann</dc:creator><dc:creator> Annemarie Koster</dc:creator><dc:creator> Emmanuel Stamatakis</dc:creator><dc:creator> Mark Hamer</dc:creator><dc:creator> ProPASS Collaboration</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> Device-measured physical activity and cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS) consortium</dc:title><dc:identifier> pmid:37950859</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad717</dc:identifier></item><item><title> Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: The C3PO NLP model developed within 1 health care system identified HF events with good agreement relative to the gold-standard CEC in an external multicenter clinical trial. Fine-tuning the model improved agreement and approximated human reproducibility. Further study is needed to determine whether NLP will improve the efficiency of future multicenter clinical trials by identifying clinical events at scale. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 11. doi: 10.1001/jamacardio.2023.4859. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: The gold standard for outcome adjudication in clinical trials is medical record review by a physician clinical events committee (CEC), which requires substantial time and expertise. Automated adjudication of medical records by natural language processing (NLP) may offer a more resource-efficient alternative but this approach has not been validated in a multicenter setting. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To externally validate the Community Care Cohort Project (C3PO) NLP model for heart failure (HF) hospitalization adjudication, which was previously developed and tested within one health care system, compared to gold-standard CEC adjudication in a multicenter clinical trial. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of the Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) trial, which compared 2 influenza vaccines in 5260 participants with cardiovascular disease at 157 sites in the US and Canada between September 2016 and January 2019. Analysis was performed from November 2022 to October 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> EXPOSURES: Individual sites submitted medical records for each hospitalization. The central INVESTED CEC and the C3PO NLP model independently adjudicated whether the cause of hospitalization was HF using the prepared hospitalization dossier. The C3PO NLP model was fine-tuned (C3PO + INVESTED) and a de novo NLP model was trained using half the INVESTED hospitalizations. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: Concordance between the C3PO NLP model HF adjudication and the gold-standard INVESTED CEC adjudication was measured by raw agreement, κ, sensitivity, and specificity. The fine-tuned and de novo INVESTED NLP models were evaluated in an internal validation cohort not used for training. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 4060 hospitalizations in 1973 patients (mean [SD] age, 66.4 [13.2] years; 514 [27.4%] female and 1432 [72.6%] male]), 1074 hospitalizations (26%) were adjudicated as HF by the CEC. There was good agreement between the C3PO NLP and CEC HF adjudications (raw agreement, 87% [95% CI, 86-88]; κ, 0.69 [95% CI, 0.66-0.72]). C3PO NLP model sensitivity was 94% (95% CI, 92-95) and specificity was 84% (95% CI, 83-85). The fine-tuned C3PO and de novo NLP models demonstrated agreement of 93% (95% CI, 92-94) and κ of 0.82 (95% CI, 0.77-0.86) and 0.83 (95% CI, 0.79-0.87), respectively, vs the CEC. CEC reviewer interrater reproducibility was 94% (95% CI, 93-95; κ, 0.85 [95% CI, 0.80-0.89]). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: The C3PO NLP model developed within 1 health care system identified HF events with good agreement relative to the gold-standard CEC in an external multicenter clinical trial. Fine-tuning the model improved agreement and approximated human reproducibility. Further study is needed to determine whether NLP will improve the efficiency of future multicenter clinical trials by identifying clinical events at scale.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950744</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4859>10.1001/jamacardio.2023.4859</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950744</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Jonathan W Cunningham</dc:creator><dc:creator> Pulkit Singh</dc:creator><dc:creator> Christopher Reeder</dc:creator><dc:creator> Brian Claggett</dc:creator><dc:creator> Pablo M Marti-Castellote</dc:creator><dc:creator> Emily S Lau</dc:creator><dc:creator> Shaan Khurshid</dc:creator><dc:creator> Puneet Batra</dc:creator><dc:creator> Steven A Lubitz</dc:creator><dc:creator> Mahnaz Maddah</dc:creator><dc:creator> Anthony Philippakis</dc:creator><dc:creator> Akshay S Desai</dc:creator><dc:creator> Patrick T Ellinor</dc:creator><dc:creator> Orly Vardeny</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:creator> Jennifer E Ho</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial</dc:title><dc:identifier> pmid:37950744</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4859</dc:identifier></item><item><title> Innovation in Event Adjudication-Human vs Machine</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 11. doi: 10.1001/jamacardio.2023.4900. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950739/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950739</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4900>10.1001/jamacardio.2023.4900</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950739</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Kenneth W Mahaffey</dc:creator><dc:creator> C Michael Gibson</dc:creator><dc:creator> Renato D Lopes</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Innovation in Event Adjudication-Human vs Machine</dc:title><dc:identifier> pmid:37950739</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4900</dc:identifier></item><item><title> Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS)</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> Background: Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization when compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy (CRT). We sought to compare the occurrence of sustained ventricular tachycardia or ventricular fibrillation (VT/VF) and new onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. Methods: This... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067465. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization when compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy (CRT). We sought to compare the occurrence of sustained ventricular tachycardia or ventricular fibrillation (VT/VF) and new onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. <b>Methods:</b> This International Collaborative LBBAP Study (I-CLAS) included patients with LVEF≤35% who underwent BVP or LBBAP for CRT between Jan 2018 to June 2022 at 15 centers. We performed propensity score matched (PS) analysis of LBBAP and BVP in a 1:1 ratio. We assessed the incidence of VT/VF and new-onset AF among patients with no prior history of AF. Time to sustained VT/VF and time to new-onset AF was analyzed using Cox proportional hazards survival model. <b>Results:</b> Among 1778 patients undergoing CRT (981-BVP, 797-LBBAP), PS matched 1414 patients (PS-BVP:707, PS-LBBAP:707). The occurrence of VT/VF was significantly lower with LBBAP compared with BVP (4.2% vs 9.3%;HR 0.46;95%CI 0.29-0.74;p&lt;0.001). The incidence of VT storm (>;3 episodes in 24 hours) was also significantly lower with LBBAP compared with BVP (0.8% vs 2.5%;p=0.013). Among 299 patients with CRT-pacemakers (BVP-111, LBBAP-188), VT/VF occurred in 8 patients in the BVP group vs. none in the LBBAP group (7.2% vs 0%;p&lt;0.001). In 1194 patients with no prior history of VT/VF or antiarrhythmic therapy (BVP-591, LBBAP-603), the occurrence of VT/VF was significantly lower with LBBAP compared with BVP (3.2% vs 7.3%;HR 0.46;95%CI 0.26-0.81;p=0.007). Among patients with no prior history of AF (n=890), the occurrence of new-onset AF >;30 seconds was significantly lower with LBBAP compared with BVP (2.8% vs 6.6%;HR 0.34;95%CI 0.16-0.73;p=0.008). The incidence of AF lasting >;24 hours was also significantly lower with LBBAP compared with BVP (0.7% vs 2.9%;p=0.015). <b>Conclusions:</b> LBBAP was associated with lower incidence of sustained VT/VF and new-onset AF compared with BVP. This difference remained significant after adjustment for differences in baseline characteristics between patients with BVP and LBBAP. Physiologic resynchronization by LBBAP may be associated with lower risk of arrhythmias compared with BVP.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950738</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067465>10.1161/CIRCULATIONAHA.123.067465</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950738</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Bengt Herweg</dc:creator><dc:creator> Parikshit S Sharma</dc:creator><dc:creator> Oscar Cano</dc:creator><dc:creator> Shunmuga Sundaram Ponnusamy</dc:creator><dc:creator> Francesco Zanon</dc:creator><dc:creator> Marek Jastrzebski</dc:creator><dc:creator> Jiangang Zou</dc:creator><dc:creator> Mihail G Chelu</dc:creator><dc:creator> Kevin Vernooy</dc:creator><dc:creator> Zachary I Whinnett</dc:creator><dc:creator> Girish M Nair</dc:creator><dc:creator> Manuel Molina-Lerma</dc:creator><dc:creator> Karol Curila</dc:creator><dc:creator> Dipen Zalavadia</dc:creator><dc:creator> Cicely Dye</dc:creator><dc:creator> Sharath C Vipparthy</dc:creator><dc:creator> Ryan Brunetti</dc:creator><dc:creator> Mishal Mumtaz</dc:creator><dc:creator> Pawel Moskal</dc:creator><dc:creator> Andrew M Leong</dc:creator><dc:creator> Antonius van Stipdonk</dc:creator><dc:creator> Jerin George</dc:creator><dc:creator> Yusuf K Qadeer</dc:creator><dc:creator> Jeffrey Kolominsky</dc:creator><dc:creator> Mehrdad Golian</dc:creator><dc:creator> Ramez Morcos</dc:creator><dc:creator> Lina Marcantoni</dc:creator><dc:creator> Faiz A Subzposh</dc:creator><dc:creator> Kenneth A Ellenbogen</dc:creator><dc:creator> Pugazhendhi Vijayaraman</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> Circulation</dc:source><dc:title> Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS)</dc:title><dc:identifier> pmid:37950738</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067465</dc:identifier></item><item><title> Neutrophil counts and cardiovascular disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Observational and genetically determined high neutrophil counts were associated with atherosclerotic cardiovascular disease, supporting that high blood neutrophil counts is a causal risk factor for atherosclerotic cardiovascular disease. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 9:ehad649. doi: 10.1093/eurheartj/ehad649. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Anti-inflammatory trials have shown considerable benefits for cardiovascular disease. High neutrophil counts, an easily accessible inflammation biomarker, are associated with atherosclerosis in experimental studies. This study aimed to investigate the associations between neutrophil counts and risk of nine cardiovascular endpoints using observational and genetic approaches. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Observational studies were conducted in the Copenhagen General Population Study (n = 101 730). Genetic studies were firstly performed using one-sample Mendelian randomization (MR) with individual-level data from the UK Biobank (n = 365 913); secondly, two-sample MR analyses were performed using summary-level data from the Blood Cell Consortium (n = 563 085). Outcomes included ischaemic heart disease, myocardial infarction, peripheral arterial disease, ischaemic cerebrovascular disease, ischaemic stroke, vascular-related dementia, vascular dementia, heart failure, and atrial fibrillation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Observational analyses showed associations between high neutrophil counts with high risks of all outcomes. In the UK Biobank, odds ratios (95% confidence intervals) per 1-SD higher genetically predicted neutrophil counts were 1.15 (1.08, 1.21) for ischaemic heart disease, 1.22 (1.12, 1.34) for myocardial infarction, and 1.19 (1.04, 1.36) for peripheral arterial disease; similar results were observed in men and women separately. In two-sample MR, corresponding estimates were 1.14 (1.05, 1.23) for ischaemic heart disease and 1.11 (1.02, 1.20) for myocardial infarction; multiple sensitivity analyses showed consistent results. No robust associations in two-sample MR analyses were found for other types of leucocytes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Observational and genetically determined high neutrophil counts were associated with atherosclerotic cardiovascular disease, supporting that high blood neutrophil counts is a causal risk factor for atherosclerotic cardiovascular disease.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950632</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad649>10.1093/eurheartj/ehad649</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950632</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Jiao Luo</dc:creator><dc:creator> Jesper Qvist Thomassen</dc:creator><dc:creator> Børge G Nordestgaard</dc:creator><dc:creator> Anne Tybjærg-Hansen</dc:creator><dc:creator> Ruth Frikke-Schmidt</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> Neutrophil counts and cardiovascular disease</dc:title><dc:identifier> pmid:37950632</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad649</dc:identifier></item><item><title> Timing treatment for tricuspid regurgitation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37950518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113071535&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 9:ehad768. doi: 10.1093/eurheartj/ehad768. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37950518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113071535&v=2.17.9.post6+86293ac">37950518</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad768>10.1093/eurheartj/ehad768</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37950518</guid><pubDate> Sat, 11 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Kush P Patel</dc:creator><dc:creator> Andreas Baumbach</dc:creator><dc:date> 2023-11-11</dc:date><dc:source> European heart journal</dc:source><dc:title> Timing treatment for tricuspid regurgitation</dc:title><dc:identifier> pmid:37950518</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad768</dc:identifier></item></channel></rss>